November 13-15, 2018

Boston, MA, USA

Twitter logo for website footers 2

Media Hub

PR TNOur Event Partner Apellis Pharmaceuticals has just secured $60m in funding to advance their C3 inhibitor APL-2 into phase III trials.

Read the full press release here.